Patients with a rare blood cancer ... Australasian Leukaemia Lymphoma Group. More information: Tycel Jovelle Phillips et al, Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From ...

has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The Food and Drug Administration (FDA) grants ...

Mantle cell lymphoma (MCL) is a rare form of cancer that affects B cells. B cells are a type of white blood in your immune system. MCL is part of a larger group of cancers called non-Hodgkin's ...

MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), resulting when B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.

Panel A shows a circulating leukemic hairy cell (arrow) in a peripheral-blood smear (May–Grünwald ... HCL variant (also called splenic B-cell lymphoma or leukemia with prominent nucleoli ...

The LyMa-101 study treated 84 patients with obinutuzumab induction, followed by autologous stem cell transplantation ... respectively, by blood (x 2 <.001). From study inclusion, the progression ...

The following is a summary of “Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized ...

mantle cell lymphoma. TP53 mutations status reported as unknown. At data cutoff, 31/60 (51.7%) patients had completed planned study treatment and remained on study, 28/60 (46.7%) had discontinued ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

Acalabrutinib plus bendamustine and rituximab led to a 27% reduction in the risk of disease progression or death in the frontline setting for older patients with mantle cell lymphoma. A study showed ...